AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01161485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
Study NCT02876328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: 0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study NCT02876328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP
Description: 1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study NCT01161485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based case management
Description: Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
Study NCT04520009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity Restriction
Description: Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
Study NCT04520009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity as Tolerated
Description: Instructions advising activity as tolerated and return to work based on patient discretion
Study NCT02876328 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study NCT02876328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study NCT02876328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV boost
Description: 1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
Study NCT00645905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
Study NCT00645905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
Study NCT00783601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo + montelukast
Description: Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
Study NCT03764267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain
Study NCT03764267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthetic
Description: general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
Study NCT00783601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
Study NCT03323346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper.
Study NCT01669447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment.
Study NCT01379742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RapidStrand seeds for use with 18g needle
Description: Rapidstrand seeds are standard size and are used with 20 g needles
Study NCT01379742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThinStrand
Description: ThinStrand seeds are smaller in diameter and used with 20g needles
Study NCT01356797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypobaric levobupivacaine with fentanyl
Description: SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
Study NCT01356797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine 0,5%
Description: SUSA with 4 mg hyperbaric bupivacaine 0.5%
Study NCT02934906 — intervention group
Intervention type: PROCEDURE
Intervention: Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion
Description: Observational study.
Study NCT02555033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: traditional resistance training
Study NCT02555033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instability resistance training
Description: training under unstable conditions
Study NCT01317745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided be sanofi pasteur
Study NCT01702168 — intervention group
Intervention type: OTHER
Intervention: Provider training: Cognitive Processing Therapy (CPT)
Study NCT04334213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501
Description: QD, PO
Study NCT04334213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745, D150
Description: QD, PO
Study NCT04334213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO
Study NCT04863196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser therapy Treatment Group
Description: laser in gastric mucosa lesion
Study NCT04863196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barrier Dust Treatment Group
Description: barrier powder in gastric mucosa lesion
Study NCT03528005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Description: 60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
Study NCT01498016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Iv busulfan 1.6mg/kg q12h D1- D4
Study NCT01393938 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Three-dimensional ultrasound
Description: Immediately following the standard of care 2D-US, for approximately 15 min.
Study NCT01447303 — intervention group
Intervention type: OTHER
Intervention: Subject outcomes following viscosupplementation of the knee
Description: The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
Study NCT02833948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Drug: Clopidogrel 75 mg OD for first 90 days
Study NCT02833948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)
Study NCT03388957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: This drug will be given before the extraction procedure
Study NCT02668029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: information already included in arm/group descriptions.
Study NCT02668029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medical air
Description: Placebo
Study NCT01554514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab intravenously 100 mg every week for four doses
Study NCT01317745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 Adjuvant
Description: Adjuvant/diluent manufactured by Novartis
Study NCT02115360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin
Description: Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
Study NCT02115360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
Study NCT00300365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone, initially 30 mg, then titrated to 45 mg/day
Study NCT00300365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo
Study NCT00300365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER
Description: Niacin ER 2.0 g/day
Study NCT01317745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
Study NCT01317745 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
Study NCT01788670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Study NCT01788670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT04716387 — intervention group
Intervention type: OTHER
Intervention: Standard LLIN
Description: Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
Study NCT04716387 — intervention group
Intervention type: OTHER
Intervention: Piperonyl butoxide ITN
Description: Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
Study NCT04716387 — intervention group
Intervention type: OTHER
Intervention: Pyriproxyfen ITN
Description: Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
Study NCT00300365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin ER
Description: Niacin ER 2.0 g/day
Study NCT00300365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: asprin 325 mg/day
Study NCT00300365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: asprin 325 mg/day
Study NCT00641082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg for 48 weeks
Study NCT00641082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: 10mg for 48 weeks
Study NCT03255876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched pomegranate juice
Description: Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
Study NCT03255876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
Study NCT02796885 — intervention group
Intervention type: OTHER
Intervention: no intervention - observational study
Study NCT02299076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral economics incentives
Description: Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
Study NCT02299076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimal incentives
Description: Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
Study NCT02078648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
Description: 1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated).
Study NCT02078648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
Study NCT02078648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-701 + GM-CSF
Description: 1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site.
Study NCT02078648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
Study NCT03169257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet plus physical activity
Description: OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
Study NCT02270255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior hypogastric nerve block
Description: 21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
Study NCT02270255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacaine
Description: 20 ml of 0.75% Ropivacaine
Study NCT04716387 — intervention group
Intervention type: OTHER
Intervention: Chlorfenapyr ITN
Description: Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
Study NCT03713203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pagetex PDT
Description: 2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
Study NCT01328821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTP-499
Description: 600 mg, 1200 mg, 1800 mg and 2400 mg
Study NCT01328821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTP-499
Description: 400 mg immediate release capsule
Study NCT02487238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Enema
Description: Active intervention.
Study NCT02487238 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Enema
Description: Placebo comparator.
Study NCT00454987 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
Study NCT00454987 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix IPV
Description: Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
Study NCT00454987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix IPV
Description: Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
Study NCT01476696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally
Study NCT03038815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACOped
Description: restriction of ankle joint motion
Study NCT03038815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho Tri
Description: restriction of ankle joint motion
Study NCT03054870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xe-133
Description: Xe-133 ventilation scintigraphy
Study NCT03054870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Technegas
Description: Technegas ventilation scintigraphy